ENVBEnveric Biosciences Inc
$1.66
$0.04
(2.47%)
Closed $1.66
$0.03
(1.81%)
After Hours
Mkt Cap$5.96M
Vol112,191.00
Fundamentals
Mkt Cap
$5.96M
Volume
-
52W High
$17.64
52W Low
$1.60
PE Ratio
-0.06
Avg. Volume
317,201.33
EPS (Annual)
-$36.24
Rev/Employee
$0.00
Earnings
-
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June...
Business Wire
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its...
Business Wire
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...
Business Wire
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...
Business Wire
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...
Business Wire
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...
Business Wire
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors PR Newswire SARASOTA, Fla...
PR Newswire
Biotech Stocks To Keep An Eye On - April 26th
Danaher, Vertex Pharmaceuticals, Medpace, argenex, Moderna, Enveric Biosciences, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science and technology to develop drugs, th...
MarketBeat
What's Going On With Enveric Biosciences Stock On Friday?
The FDA issues priority vouchers and clears early trials for ibogaine derivatives for using psychedelics for therapy and mental health.read more...
Benzinga
<
1
2
...
>
Advertisement|Remove ads.
Latest ENVB News
ViewEnveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Business Wire
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Business Wire
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Business Wire
Advertisement|Remove ads.